AngioDynamics (NASDAQ:ANGO) Issues Quarterly Earnings Results

AngioDynamics (NASDAQ:ANGO) announced its quarterly earnings data on Wednesday. The medical instruments supplier reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.07, RTT News reports. AngioDynamics had a negative return on equity of 5.86% and a negative net margin of 83.95%. The business had revenue of $72.90 million for the quarter, compared to analyst estimates of $70.93 million. During the same period in the prior year, the company earned ($0.05) earnings per share. The company’s revenue was down .1% on a year-over-year basis. AngioDynamics updated its FY 2025 guidance to -0.380–0.340 EPS and its FY25 guidance to ($0.38)-($0.34) EPS.

AngioDynamics Stock Up 37.7 %

AngioDynamics stock opened at $12.94 on Friday. AngioDynamics has a 52 week low of $5.26 and a 52 week high of $13.13. The firm has a market cap of $525.80 million, a price-to-earnings ratio of -2.12 and a beta of 0.59. The business’s 50-day moving average price is $8.12 and its 200 day moving average price is $7.38.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Canaccord Genuity Group cut their price target on shares of AngioDynamics from $13.00 to $12.00 and set a “buy” rating on the stock in a report on Friday, October 4th. HC Wainwright reissued a “buy” rating and set a $14.00 target price on shares of AngioDynamics in a report on Tuesday, December 10th.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.